Literature DB >> 12906916

Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.

Ming Zhao1, Ping He, Michelle A Rudek, Manuel Hidalgo, Sharyn D Baker.   

Abstract

A new simple and specific method was developed and validated for the quantitative determination of OSI-774 (Tarceva, Erlotinib) and its metabolite, OSI-420, in human plasma. Sample pretreatment involved a single protein precipitation step with acetonitrile. The analytes were separated on Waters X-Terra C(18) (50 x 2.1 mm I.D., 3.5 microm) analytical column and eluted with acetonitrile-water mobile (70:30, v/v) containing 0.1% formic acid. The analytes of interest were monitored by tandem mass spectrometry with electrospray positive ionization. The overall extraction efficiency was greater than 88% for OSI-774 and 62% for OSI-420, with values for within-day and between-day precision and accuracy of <15%. Compared to previous assays, this method is simple, specific, and reproducible and will be used to characterize the plasma pharmacokinetics of OSI-774 at doses of 50 to 150 mg to optimize treatment with this agent.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12906916     DOI： 10.1016/s1570-0232(03)00356-8

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN： 1570-0232            Impact factor:   3.205


  23 in total

1.  A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.

Authors:  Jill Gilbert; Michelle A Rudek; Michaela J Higgins; Ming Zhao; Sara Bienvenu; Nancy Tsottles; Muhammad A Chaudhry; Richard Wahl; Arlene Forastiere; Maura Gillison
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

2.  Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.

Authors:  Birgit Geoerger; Darren Hargrave; Fabienne Thomas; Anna Ndiaye; Didier Frappaz; Felipe Andreiuolo; Pascale Varlet; Isabelle Aerts; Riccardo Riccardi; Timothy Jaspan; Etienne Chatelut; Marie-Cecile Le Deley; Xavier Paoletti; Christian Saint-Rose; Pierre Leblond; Bruce Morland; Jean-Claude Gentet; Valérie Méresse; Gilles Vassal
Journal:  Neuro Oncol       Date:  2010-10-25       Impact factor: 12.300

3.  Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.

Authors:  Wells A Messersmith; Antonio Jimeno; Heather Jacene; Ming Zhao; Piotr Kulesza; Daniel A Laheru; Yasmin Kahn; Alexander Spira; Janet Dancey; Christine Iacobuzio-Donahue; Ross C Donehower; Michael Carducci; Michelle A Rudek; Manuel Hidalgo
Journal:  Clin Colorectal Cancer       Date:  2010-12       Impact factor: 4.481

4.  Therapeutic drug monitoring and tyrosine kinase inhibitors.

Authors:  Pauline Herviou; Emilie Thivat; Damien Richard; Lucie Roche; Joyce Dohou; Mélanie Pouget; Alain Eschalier; Xavier Durando; Nicolas Authier
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

5.  Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Authors:  Eric B Haura; Tawee Tanvetyanon; Alberto Chiappori; Charles Williams; George Simon; Scott Antonia; Jhanelle Gray; Sharon Litschauer; Leticia Tetteh; Anthony Neuger; Lanxi Song; Bhupendra Rawal; Michael J Schell; Gerold Bepler
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

6.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

Authors:  David M Peereboom; Manmeet S Ahluwalia; Xiaobu Ye; Jeffrey G Supko; Sarah L Hilderbrand; Surasak Phuphanich; L Burt Nabors; Myrna R Rosenfeld; Tom Mikkelsen; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

7.  A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.

Authors:  Carolyn D Britten; Richard S Finn; Linda D Bosserman; Steven G Wong; Michael F Press; Mubashira Malik; Bert L Lum; Dennis J Slamon
Journal:  Clin Breast Cancer       Date:  2009-02       Impact factor: 3.225

8.  Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.

Authors:  T W Flaig; L J Costa; D L Gustafson; K Breaker; M K Schultz; F Crighton; F J Kim; H Drabkin
Journal:  Br J Cancer       Date:  2010-09-07       Impact factor: 7.640

9.  A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

Authors:  Jhanelle E Gray; Eric Haura; Alberto Chiappori; Tawee Tanvetyanon; Charles C Williams; Mary Pinder-Schenck; Julie A Kish; Jenny Kreahling; Richard Lush; Anthony Neuger; Leticia Tetteh; Angela Akar; Xiuhua Zhao; Michael J Schell; Gerold Bepler; Soner Altiok
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

10.  Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.

Authors:  John F Deeken; Jan H Beumer; Nicole M Anders; Teresia Wanjiku; Milan Rusnak; Michelle A Rudek
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-02       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.